Open AccessLomustine, cytarabine, cyclophosphamide, etoposide – An effective conditioning regimen in autologous hematopoietic stem cell transplant for primary refractory or relapsed lymphoma: Analysis of toxicity, long-term outcome, and prognostic factors
Author(s) -
Alok Gupta,
Anant Gokarn,
Deepan Rajamanickam,
Sachin Punatar,
Ravi Thippeswamy,
Libin Mathew,
Bhausaheb Bagal,
Sadhana Kannan,
Navin Khattry
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.181183
Subject(s) - medicine , etoposide , gastroenterology , lomustine , mucositis , surgery , cyclophosphamide , cytarabine , transplantation , hematopoietic stem cell transplantation , chemotherapy , oncology , vincristine
High-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HSCT) is the treatment of choice for patients with relapsed and refractory (RR) lymphoma. We analyzed toxicity and long-term outcome with lomustine, cytarabine, cyclophosphamide, etoposide (LACE) conditioning in patients with primary refractory or relapsed lymphoma undergoing autologous transplant.